# Peptide Drugs Sector

Canonical URL: https://biopharmsignal.com/sector/peptide-drugs

Peptide Drugs includes companies developing therapies built from short chains of amino acids. These programs often sit between small molecules and biologics in terms of design flexibility, and they are used across metabolic disease, endocrinology, oncology, and other therapeutic areas.

Companies currently grouped under Peptide Drugs: 5

## Recent Sector News

- 2026-05-19 08:15 EST — PTIX — [Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-advisor-and-danforth-health-as-strategic-operations-partner) — Source: Protagenic Therapeutics
- 2026-04-23 08:15 EST — PTIX — [Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advancement-of-first-in-class-tcap-pathway-therapy-pt00114) — Source: Protagenic Therapeutics
- 2026-03-17 08:00 EST — PTIX — [Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-phytanix-separation-strengthens-balance-sheet-and-repositions-the-company-around-pt00114) — Source: Protagenic Therapeutics
- 2026-03-10 08:00 EST — PTIX — [Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market) — Source: Protagenic Therapeutics
- 2025-12-09 08:46 EST — PTIX — [Results from Phase 1 Multiple-Dose Study of PT00114](https://biopharmsignal.com/news/PTIX/results-from-phase-1-multiple-dose-study-of-pt00114) — Source: Protagenic Therapeutics
- 2025-11-13 08:22 EST — PTIX — [Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-completion-of-enrollment-and-dosing-in-phase-1-mad-study) — Source: Protagenic Therapeutics
- 2025-08-22 17:25 EST — PTIX — [Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-provides-update-on-form-10-q-filing-timeline-and-nasdaq-compliance) — Source: Protagenic Therapeutics
- 2025-08-21 08:12 EST — PTIX — [Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-advances-pt00114-into-multiple-dose-phase-1-trial-positioning-for-phase-2-in-stress-and-mood-disorders) — Source: Protagenic Therapeutics
- 2025-07-30 08:30 EST — PTIX — [Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-program-drug-candidates) — Source: Protagenic Therapeutics
- 2025-05-21 09:15 EST — PTIX — [Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-receives-3-1-million-from-recent-warrant-activity) — Source: Protagenic Therapeutics
- 2025-05-19 07:43 EST — PTIX — [Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-and-phytanix-announce-business-combination-to-form-neuroactive-biopharmaceutical-company-with-six-drug-candidates-in-development-including-treatments-for-obesity-and-metabolic-disorders) — Source: Protagenic Therapeutics
- 2025-04-29 16:00 EST — PTIX — [Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-to-effect-1-for-14-reverse-stock-split) — Source: Protagenic Therapeutics
- 2024-11-05 08:12 EST — PTIX — [Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-closing-of-private-placement-for-aggregate-gross-proceeds-of-1-275-million) — Source: Protagenic Therapeutics
- 2024-05-22 08:12 EST — PTIX — [Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-stress-regulating-peptide-demonstrates-exceptional-safety-in-single-dose-portion-of-phase-i-trial-paving-the-way-for-next-steps-toward-potential-breakthrough-treatments-in-stress-related-neuropsychiatric-disorders) — Source: Protagenic Therapeutics
- 2024-05-01 08:38 EST — PTIX — [Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-enrollment-in-single-dose-portion-of-phase-1-of-innovative-stress-disorder-trial) — Source: Protagenic Therapeutics
- 2024-04-17 08:42 EST — PTIX — [Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-innovative-peptide-pt00114-to-be-highlighted-at-boston-summit) — Source: Protagenic Therapeutics
- 2024-04-01 16:20 EST — PTIX — [Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-reports-fourth-quarter-and-full-year-2023-results) — Source: Protagenic Therapeutics
- 2024-03-27 08:42 EST — PTIX — [Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-successfully-concludes-third-cohort-in-single-dose-portion-of-phase-1-trial-for-stress-related-neuropsychiatric-disorders) — Source: Protagenic Therapeutics
- 2024-03-25 17:00 EST — PTIX — [Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-schedules-first-q4-and-fy-2023-earnings-call) — Source: Protagenic Therapeutics
- 2024-03-21 08:41 EST — PTIX — [Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-resolution-of-nasdaq-deficiency-notice) — Source: Protagenic Therapeutics

## Companies

- [AMTI](https://biopharmsignal.com/company/AMTI) — Applied Molecular Transport
- [BCYC](https://biopharmsignal.com/company/BCYC) — Bicycle Therapeutics
- [ENTX](https://biopharmsignal.com/company/ENTX) — Entera Bio
- [PTIX](https://biopharmsignal.com/company/PTIX) — Protagenic Therapeutics
- [PTGX](https://biopharmsignal.com/company/PTGX) — Protagonist Therapeutics Inc